Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ vomiting compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) may leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether low‐frequency electroacupuncture changes adverse eventsc compared with physical exercise or no intervention (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).